| Indication | Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
| Pharmacodynamics | Enprofylline is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity. |
| Mechanism of action | Enprofylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, enprofylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. |
| Absorption | Rapidly absorbed from the digestive tract |
| Volume of distribution | Not Available |
| Protein binding | 49% |
| Metabolism | Not Available |
| Route of elimination | Not Available |
| Half life | 1.9 hours |
| Clearance | Not Available |
| Toxicity | Not Available |
No comments:
Post a Comment